Tagged as: Teva

Alvotech and DKSH Extend Partnership in Asia

Alvotech and DKSH recently announced an expansion of their strategic partnership to commercialize six new biosimilar candidates for the Asian markets.  The press release does not name the biosimilar candidates, but states that they “address[] multiple therapeutic areas.”  The companies previously entered into an exclusive license partnership for Alvotech’s adalimumab…

Read More

Alvotech and Teva Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

Today Alvotech and Teva announced that they have entered into an exclusive strategic partnership for the commercialization of five biosimilar candidates in the U.S.  Under the partnership agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, and Teva will be exclusively commercializing the products in…

Read More

Genentech Settles Rituximab Patent Dispute with Celltrion and Teva

On November 1, 2018, Genentech and its co-plaintiffs dismissed the lawsuits they brought against Celltrion and Teva under the BPCIA in the District of New Jersey, in which the plaintiffs alleged that Celltrion’s filing of an aBLA relating to Truxima®, Celltrion’s proposed biosimilar to Rituxan® (rituximab), infringed certain patents.  The…

Read More